Ponesimod for the treatment of relapsing multiple sclerosis

References

• Compston A, Coles A. Multiple sclerosis. Lancet. 2008 Oct 25;372(9648):1502–1517.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL. Epidemiology of multiple sclerosis: from risk factors to prevention-an update. Semin Neurol. 2016 Apr;36(2):103–114.
   PubMed Web of Science ®Google Scholar
• Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother. 2013 Dec;13(12 Suppl):3–9.
   PubMed Web of Science ®Google Scholar
• MSIF. Atlas of MS 2013; 2013.
   Google Scholar
• Wallin MT, Culpepper WJ, Nichols E, et al. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019 Mar 01;18(3):269–285.
   PubMed Web of Science ®Google Scholar
• Mansouri S, Zayeri F. Global and regional trends of multiple sclerosis disability-adjusted life years rates: a 25-year assessment. Neuroepidemiology. 2019;52(1–2):17–24.
   PubMed Web of Science ®Google Scholar
• Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72(Suppl 1):1–5.
   PubMed Web of Science ®Google Scholar
• Derfuss T, Mehling M, Papadopoulou A, et al. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol. 2020 Apr;19(4):336–347.
   PubMed Web of Science ®Google Scholar
• Rae-Grant A, Day GS, Marrie RA, et al. Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology. Neurology. 2018 Apr 24;90(17):789–800.
   PubMed Web of Science ®Google Scholar
• Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics. 2017 Oct;14(4):859–873.
   PubMed Web of Science ®Google Scholar
• Hla T, Brinkmann V. Sphingosine 1-phosphate (S1P). Physiology and the effects of S1P receptor modulation. Neurology. 2011;76(8 Supplement 3):S3–S8.
   Google Scholar
• Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs. 2015 Jul;29(7):565–575.
   PubMed Web of Science ®Google Scholar
• Hunter SF, Bowen JD, Reder AT. The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis. CNS Drugs. 2016 Feb;30(2):135–147.
   PubMed Web of Science ®Google Scholar
• Maceyka M, Harikumar KB, Milstien S, et al. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012 Jan;22(1):50–60.
   PubMed Web of Science ®Google Scholar
• Pyne NJ, Pyne S. Sphingosine 1-phosphate receptor 1 signaling in mammalian cells. Molecules. 2017 Feb 23;22(3):344.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):387–401.
   PubMed Web of Science ®Google Scholar
• Kappos L, Antel J, Comi G, et al. Oral Fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124.
   PubMed Web of Science ®Google Scholar
• Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010 Mar-Apr;33(2):91–101.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010 Nov;9(11):883–897.
   PubMed Web of Science ®Google Scholar
• Kim YM, Sachs T, Asavaroengchai W, et al. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest. 2003 Mar;111(5):659–669.
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun;13(6):545–556.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Khatri B, Barkhof F, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016 May;87(5):468–475.
   PubMed Web of Science ®Google Scholar
• Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011 Jun;10(6):520–529.
   PubMed Web of Science ®Google Scholar
• Zecri FJ. From natural product to the first oral treatment for multiple sclerosis: the discovery of FTY720 (Gilenya)? Curr Opin Chem Biol. 2016 Jun;32:60–66.
   PubMed Web of Science ®Google Scholar
• Mao-Draayer Y, Sarazin J, Fox D, et al. The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases. Clin Immunol. 2017 Feb;175:10–15.
   PubMed Web of Science ®Google Scholar
• EMA; 2018 [cited 2020 Apr 07]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya#authorisation-details-section
   Google Scholar
• Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12;387(10023):1075–1084.
   PubMed Web of Science ®Google Scholar
• Gold R, Comi G, Palace J, et al. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol. 2014 Feb;261(2):267–276.
   PubMed Web of Science ®Google Scholar
• Boudot de la Motte M, Louapre C, Bertrand A, et al. Extensive white matter lesions after 2 years of fingolimod: progressive multifocal leukoencephalopathy or MS relapse? Mult Scler ( (Houndmills, Basingstoke, England)). 2017 Apr;23(4):614–616.
   PubMed Web of Science ®Google Scholar
• Alping P, Askling J, Burman J, et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol. 2020;87(5):688–699.
   PubMed Web of Science ®Google Scholar
• EMA. Updated restrictions for Gilenya: multiple sclerosis medicine not to be used in pregnancy. 2019.
   Google Scholar
• Pan S, Gray NS, Gao W, et al. Discovery of BAF312 (Siponimod), a potent and selective s1p receptor modulator. ACS Med Chem Lett. 2013 Mar 14;4(3):333–337.
   PubMed Web of Science ®Google Scholar
• Dumitrescu L, Constantinescu CS, Tanasescu R. Siponimod for the treatment of secondary progressive multiple sclerosis. Expert Opin Pharmacother. 2019 Feb;20(2):143–150.
   PubMed Web of Science ®Google Scholar
• Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013 Aug;12(8):756–767.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li DK, Stuve O, et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol. 2016 Sep 1;73(9):1089–1098.
   PubMed Web of Science ®Google Scholar
• ANZCTR; 2013 [cited 2020 Apr 07]. Available from: http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12613000545763
   Google Scholar
• Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018 Mar 31;391(10127):1263–1273.
   PubMed Web of Science ®Google Scholar
• Legangneux E, Gardin A, Johns D. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br J Clin Pharmacol. 2013 Mar;75(3):831.
   PubMed Web of Science ®Google Scholar
• Legangneux E, Shakeri-Nejad K, Aslanis V, et al. Cardiac effects of siponimod (BAF312) re-initiation after variable periods of drug discontinuation in healthy subjects. Clin Ther. 2016 Mar;38(3):631–45. e1.
   PubMed Web of Science ®Google Scholar
• EMA. Mayzent siponimod; 2020 [cited 2020 Mar]. Available from: h ttps://www.ema.europa.eu/en/medicines/human/EPAR/mayzent
   Google Scholar
• FDA. Drug approval package: mayzent (siponimod); 2019 [cited 2020 Mar.]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000TOC.cfm
   Google Scholar
• Government A. Australian public assessment report for siponimod; 2019.
   Google Scholar
• Cohen JA, Arnold DL, Comi G, et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Apr;15(4):373–381.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Comi G, Arnold DL, et al. Efficacy and safety of ozanimod in multiple sclerosis: dose-blinded extension of a randomized phase II study. Mult Scler. 2019 Aug;25(9):1255–1262.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Comi G, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019 Nov;18(11):1021–1033.
   PubMed Web of Science ®Google Scholar
• Comi G, Kappos L, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019 Nov;18(11):1009–1020.
   PubMed Web of Science ®Google Scholar
• EMA. Zeposia – ozanimod; 2020 [cited 2020 Apr]. Available from: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/zeposia
   Google Scholar
• FDA. Drug trials snapshots: ZEPOSIA; 2020 [cited 2020 Apr]. Available from: https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-zeposia
   Google Scholar
• Bolli MH, Abele S, Binkert C, et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 RECEPTOR AGONISTS. J Med Chem. 2010 May 27;53(10):4198–4211.
   PubMed Web of Science ®Google Scholar
• Piali L, Froidevaux S, Hess P, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011 May;337(2):547.
   PubMed Web of Science ®Google Scholar
• Dash RP, Rais R, Srinivas NR. Ponesimod, a selective sphingosine 1-phosphate (S1P1) receptor modulator for autoimmune diseases: review of clinical pharmacokinetics and drug disposition. Xenobiotica. 2018 May;48(5):442.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio D, Freedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Ther Adv Chronic Dis. 2016;7(1):18–33.
   PubMed Web of Science ®Google Scholar
• Brossard P, Scherz M, Halabi A, et al. Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration. J Clin Pharmacol. 2014 Feb;54(2):179–188.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio D, Steinmann J, Brossard P, et al. Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations. Immunopharmacol Immunotoxicol. 2015 Feb;37(1):103–109.
   PubMed Web of Science ®Google Scholar
• Olsson T, Boster A, Fernandez O, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1198–1208.
   PubMed Web of Science ®Google Scholar
• Brossard P, Derendorf H, Xu J, et al. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013;76(6):888–896.
   PubMed Web of Science ®Google Scholar
• Reyes M, Hoch M, Brossard P, et al. Effects of ethnicity and sex on the pharmacokinetics and pharmacodynamics of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod: a clinical study in Japanese and Caucasian subjects. Pharmacology. 2014;94(5–6):223–229.
   PubMed Web of Science ®Google Scholar
• Pouzol L, Piali L, Bernard CC, et al. Therapeutic potential of ponesimod alone and in combination with dimethyl fumarate in experimental models of multiple sclerosis. Innov Clin Neurosci. 2019 Mar 1; 16(3–4):22–30.
   PubMedGoogle Scholar
• ClinicalTrials.gov Clinical study to investigate the long-term safety, tolerability, and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis- NCT01093326; 2010 [cited 2020 Mar]. Available from: https://clinicaltrials.gov/ct2/show/NCT01093326
   Google Scholar
• ClinicalTrials.gov. Oral ponesimod versus teriflunomide in relapsing multiple sclerosis (OPTIMUM) - NCT02425644; 2015 [cited 2020 Mar]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02425644?term=ponesimod&cond=Multiple+Sclerosis&draw=2
   Google Scholar
• Kappos L, Burcklen M, Freedman MS, et al. Efficacy and safety of ponesimod compared to teriflunomide in patients with relapsing multiple sclerosis: results of the randomized, active-controlled, double-blind, parallel-group phase 3 OPTIMUM study. ECTRIMS. Ed; 2019.
   Google Scholar
• ClinicalTrials.gov. Long-term extension to study AC-058B301 to investigate safety, tolerability and disease control of ponesimod 20 mg in patients with relapsing multiple sclerosis (OPTIMUM-LT) NCT03232073. 2017; 2020 January 22 [cited 2020 Apr]. Available from: https://clinicaltrials.gov/ct2/show/NCT03232073?cond=ponesimod
   Google Scholar
• ClinicalTrials.gov. Clinical study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are Treated With dimethyl fumarate (Tecfidera®) (POINT) - NCT02907177; 2016 [cited 2020 06 Mar 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT02907177
   Google Scholar
• Reyes M, Brossard P, Chassard D, et al. Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive. Eur J Clin Pharmacol. 2014 Mar;70(3):287–293.
   PubMed Web of Science ®Google Scholar
• Juif PE, Hoch M, Vaclavkova A, et al. Mitigation of initial cardiodynamic effects of the S1P1 receptor modulator ponesimod using a novel up-titration regimen. J Clin Pharmacol. 2017 Mar;57(3):401–410.
   PubMed Web of Science ®Google Scholar
• Schmouder R, Serra D, Wang Y, et al. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol. 2006;46(8):895–904.
   PubMed Web of Science ®Google Scholar
• Schmouder R, Hariry S, David OJ. Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol. 2012 Apr 01;68(4):355–362.
   PubMed Web of Science ®Google Scholar